Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Cancers · 16.07.2023 · 15 (14) · 3642
DOI: 10.3390/cancers15143642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.07.2023. Verfasst von Sayra Dilmac und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The recent success of Poly (ADP-ribose) polymerase (PARP) inhibitors has led to the approval of four different PARP inhibitors for the treatment of BRCA1/2-mutant breast and ovarian cancers. About 40–50% of BRCA1/2-mutated patients do not respond to PARP inhibitors due to a preexisting innate or intrinsic resistance; the majority of patients who initially respond to the therapy inevitably develop acquired resistance. However, subsets of patients experience a long-term response (>2 years) to treatment with PARP inhibitors. Poly (ADP-ribose) polymerase 1 (PARP1) is an enzyme that plays an important role in the recognition and repair of DNA damage. PARP inhibitors induce “synthetic lethality” in patients with tumors with a homologous-recombination-deficiency (HRD). Several molecular mechanisms have been identified as causing PARP-inhibitor-resistance. In this review, we focus on the molecular mechanisms underlying the PARP-inhibitor-resistance in BRCA-mutated breast cancer and summarize potential therapeutic strategies to overcome the resistance mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
- Houston Methodist Neal Cancer Center, Houston, TX 77030, USA.
Zitieren
APA
Dilmac, S., & Ozpolat, B. (2023). Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Cancers, 15(14), 3642. https://doi.org/10.3390/cancers15143642
Vancouver
Dilmac S, Ozpolat B. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Cancers. 2023;15(14):3642. doi:10.3390/cancers15143642
BibTeX
@article{Dilmac2023,
author = {Dilmac, Sayra and Ozpolat, Bulent},
title = {Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches},
journal = {Cancers},
year = {2023},
volume = {15},
number = {14},
pages = {3642},
doi = {10.3390/cancers15143642}
}
EUVIMED